First in Human Study of AZD9592 in Solid Tumors

ClinicalTrials.gov ID: NCT05647122

Public ClinicalTrials.gov record NCT05647122. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.

Study identification

NCT ID: NCT05647122
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 167 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 20, 2022
Primary completion: Aug 2, 2028
Completion: Aug 2, 2028
Last update posted: Jun 10, 2026

2022 – 2028

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Site	Duarte	California	91010	—
Research Site	North Haven	Connecticut	06473	—
Research Site	Washington D.C.	District of Columbia	20016	—
Research Site	Chicago	Illinois	60637	—
Research Site	Baltimore	Maryland	21224	—
Research Site	Baltimore	Maryland	21231	—
Research Site	Milford	Massachusetts	01757	—
Research Site	Mineola	New York	11501	—
Research Site	New York	New York	10016	—
Research Site	New York	New York	10021	—
Research Site	New York	New York	10029	—
Research Site	Philadelphia	Pennsylvania	19104	—
Research Site	Providence	Rhode Island	02903	—
Research Site	Houston	Texas	77030	—
Research Site	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05647122, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 10, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05647122 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →